血液形成可以通过纠正异常的骨髓巨细胞极化在无塑性贫血患者的改善
Chen-Yuan Li1, Dan-Dan Chen1, Xin-Yan Zhang1
1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China.
Science China. Life sciences
|February 15, 2026
概括
骨髓微环境中的异常巨细胞两极分化有助于无塑性贫血 (AA). 血栓形成素受体激动剂 (TPO-RA) 异血组组 (HET) 可以纠正这种不平衡,改善AA患者的血液形成和免疫功能.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 无形性贫血 (AA) 的发病因子尚未完全理解,尽管血液造血干细胞 (HSC) 的免疫媒介破坏是一种已知的机制.
- 骨髓 (BM) 微环境中M1和M2巨细胞 (MΦs) 的异常极化会影响血液形成和免疫调节.
- 以前的研究表明,MΦs在移植后的造血复合中起着作用,暗示它们参与AA.
研究的目的:
- 为了调查异常的骨髓巨分化是否参与了无塑性贫血的发生.
- 探索AA中异常MΦ偏振的潜在机制,包括PI3K/AKT通路.
- 为了确定血栓形成素受体激动剂 (TPO-RA) 血栓形成剂 (HET) 对BM MΦ两极化的作用及其对AA中的血液形成和免疫的影响.
主要方法:
- 建立了AA的经典小鼠模型,并与AA患者和健康对照 (HCs) 进行了前性病例控制研究.
- 分析了使用流细胞计,RNA-seq,PCR和Western blot的BM MΦ两极化.
- 利用在实验室内对用HET或不使用HET治疗的HSC/T细胞和BM MΦ进行协同培养试验,以评估其影响.
主要成果:
- 患有AA的小鼠表现出异常的BM MΦ两极化 (M1增加,M2减少),与造血失败相关.
- AA患者表现出类似的异常BM MΦ极化,与PI3K/AKT通路的下调有关.
- 在AA患者中,HET治疗纠正了异常的MΦ极化,改善了血液形成和免疫功能,可能通过PI3K/AKT通路激活.
结论:
- 异常的骨髓巨细胞两极分化与无塑性贫血的发病有关.
- 一种TPO-RA的Hetrombopag (HET) 显示出在改造BM MΦ两极化和恢复AA中的造血和免疫功能的潜力.
- 准BM MΦ两极化可能是一个新的治疗策略,用于改善AA患者的临床反应,特别是与IST结合使用.
相关概念视频
01:01Regulation of Hematopoietic Stem Cells
4.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.1K
01:22Bone Marrow Sampling and Transplants
1.5K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.5K
01:20Overview of Hematopoiesis
9.9K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
9.9K
01:15Differentiation of Common Myeloid Progenitor Cells
4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K